Diffusion Pharmaceuticals Stock Net Income
| DFFNDelisted Stock | USD 4.62 0.07 1.54% |
Diffusion Pharmaceuticals fundamentals help investors to digest information that contributes to Diffusion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Diffusion Stock. The fundamental analysis module provides a way to measure Diffusion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diffusion Pharmaceuticals stock.
Diffusion |
Diffusion Pharmaceuticals Company Net Income Analysis
Diffusion Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Diffusion Pharmaceuticals Net Income | (15.59 M) |
Most of Diffusion Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diffusion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Diffusion Pharmaceuticals reported net income of (15.59 Million). This is 104.57% lower than that of the Biotechnology sector and 122.26% lower than that of the Health Care industry. The net income for all United States stocks is 102.73% higher than that of the company.
Diffusion Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diffusion Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diffusion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Diffusion Pharmaceuticals by comparing valuation metrics of similar companies.Diffusion Pharmaceuticals is currently under evaluation in net income category among related companies.
Diffusion Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | (6.02 M) | |||
| Shares Outstanding | 2.04 M | |||
| Shares Owned By Insiders | 0.23 % | |||
| Shares Owned By Institutions | 10.27 % | |||
| Number Of Shares Shorted | 2.54 K | |||
| Price To Earning | (0.60) X | |||
| Price To Book | 0.51 X | |||
| EBITDA | (15.97 M) | |||
| Net Income | (15.59 M) | |||
| Cash And Equivalents | 25.86 M | |||
| Cash Per Share | 12.68 X | |||
| Total Debt | 67.89 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 11.59 X | |||
| Book Value Per Share | 6.97 X | |||
| Cash Flow From Operations | (14.97 M) | |||
| Short Ratio | 0.29 X | |||
| Earnings Per Share | (7.11) X | |||
| Target Price | 40.0 | |||
| Number Of Employees | 13 | |||
| Beta | 1.76 | |||
| Market Capitalization | 8.98 M | |||
| Total Asset | 22.64 M | |||
| Retained Earnings | (145.6 M) | |||
| Working Capital | 20.22 M | |||
| Current Asset | 3.29 M | |||
| Current Liabilities | 3.68 M | |||
| Z Score | 69.08 | |||
| Net Asset | 22.64 M |
About Diffusion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diffusion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diffusion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diffusion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Diffusion Pharmaceuticals information on this page should be used as a complementary analysis to other Diffusion Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Diffusion Stock
If you are still planning to invest in Diffusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Diffusion Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |